- 1 **Title:** Autoimmune profiling suggests paraneoplastic etiology in pediatric ROHHAD 2
- 3 Caleigh Mandel-Brehm^{*}, PhD, Department of Biochemistry and Biophysics, University
- 4 of California, San Francisco, CA
- 5 Leslie A. Benson*, MD, Department of Neurology, Harvard Medical School, Boston, MA
- 6 Baouyen Tran*, PhD, Weill Institute for Neurosciences, Department of Neurology,
- 7 University of California, San Francisco, CA
- 8 Andrew F. Kung, BA, Department of Biochemistry and Biophysics, University of
- 9 California, San Francisco, CA
- 10 Sabrina A. Mann, Department of Biochemistry and Biophysics, University of California,
- 11 San Francisco, CA
- 12 Sara E. Vazguez, BS, Department of Biochemistry and Biophysics, University of
- 13 California, San Francisco, CA
- 14 Hanna Retallack, PhD, Department of Biochemistry and Biophysics, University of
- 15 California, San Francisco, CA
- 16 Hannah A. Sample, BS, Department of Biochemistry and Biophysics, University of
- 17 California, San Francisco, CA
- 18 Kelsey C. Zorn, MHS, Department of Biochemistry and Biophysics, University of
- 19 California, San Francisco, CA
- 20 Lillian M. Khan, BS, Department of Biochemistry and Biophysics, University of
- 21 California, San Francisco, CA
- 22 Lauren M. Kerr, BA, Department of Neurology, Boston Children's Hospital, Boston, MA

- 23 Patrick L. McAlpine, BS, Otolaryngology Head and Neck Surgery Research Division,
- 24 Stanford University, Stanford, CA
- 25 Lichao Zhang, PhD, Chan Zuckerberg Biohub, Stanford, CA
- 26 Frank McCarthy, BS, Chan Zuckerberg Biohub, Stanford, CA
- 27 Joshua E. Elias, PhD, Chan Zuckerberg Biohub, Stanford, CA
- 28 Umakanth Katwa, MD, Department of Pulmonary Medicine, Sleep Center, Boston
- 29 Children's Hospital, Boston, MA
- 30 Christina M. Astley, MD, ScD Division of Endocrinology & Computational Epidemiology,
- 31 Boston Children's Hospital, Boston, MA
- 32 Stuart Tomko, MD, Department of Neurology, Washington University, St. Louis, MO
- 33 Josep Dalmau, MD, PhD, Catalan Institution for Research and Advanced Studies
- 34 (ICREA), Hospital Clinic-Idibaps, University of Barcelona, Barcelona, Spain
- 35 William W. Seeley, MD, Memory and Aging Center, Department of Neurology,
- 36 University of California, San Francisco, CA
- 37 Samuel J. Pleasure, MD, PhD, Weill Institute for Neurosciences, Department of
- 38 Neurology, University of California, San Francisco, CA
- 39 Michael R. Wilson, MD, MAS, Weill Institute for Neurosciences, Department of
- 40 Neurology, University of California, San Francisco, CA
- 41 Mark P. Gorman**, MD, Department of Neurology, Harvard Medical School, Boston, MA
- 42 Joseph L. DeRisi**, PhD, Chan Zuckerberg Biohub, Department of Biochemistry and
- 43 Biophysics, University of California, San Francisco, CA
- 44
- 45 *Authors contributed equally to this work

****Co-Corresponding authors**

Corresponding Author Information

- 48 Name: Mark P. Gorman
- 49 Address: 300 Longwood Ave, Boston, MA, 02115
- 50 Email: mark.gorman@childrens.harvard.edu
- 51 Phone: 857-218-4794
- 53 Name: Joseph L. DeRisi
- 54 Address: 1700 4th street, QB3 room 404, San Francisco, CA 94110
- 55 Email: joe@derisilab.ucsf.edu
- 56 Phone: 415-418-4794

- (0

69 Abstract

70 ROHHAD (Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and 71 Autonomic Dysregulation) is a rare, yet severe pediatric disorder resulting in 72 hypothalamic dysfunction and frequent sudden death. Genetic and other investigations 73 have failed to identify an etiology or diagnostic test. Frequent co-occurrence of 74 neuroblastic tumors (NTs) and cerebrospinal fluid inflammation point to an autoimmune 75 paraneoplastic neurological syndrome (PNS); however, specific anti-neural autoantibodies, a hallmark of PNS, have not been identified. Here, we screened 76 77 antibodies from a curated cohort of ROHHAD patients (n=9) and controls (n=150) using 78 a programmable phage display of the human peptidome (PhIP-Seg). Our ROHHAD 79 cohort exhibited frequent association with NTs (8/9) and features consistent with 80 autoimmune etiology. Autoantibodies to Zinc finger and SCAN domain-containing 81 protein 1 (ZSCAN1) were discovered and orthogonally validated in 7 of 9 ROHHAD 82 patients, all of whom had NTs, and shown to be absent in non-ROHHAD pediatric 83 patients with NTs. Notably, human ZSCAN1 expression was confirmed in ROHHAD 84 tumor and healthy human hypothalamus. Our results support the notion that tumor-85 associated ROHHAD is a pediatric PNS, potentially initiated by an immune response to 86 peripheral NT. ZSCAN1 autoantibodies may aid in an accurate diagnosis of ROHHAD, 87 thus providing a means toward early detection and treatment. Lastly, given the absence 88 of the ZSCAN1 gene in rodents, our study highlights the value of human-based 89 approaches in addition to the classical rodent-based approaches for detecting novel 90 PNS subtypes.

91

92 Main

93 Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic 94 Dysregulation (ROHHAD) is a poorly understood pediatric syndrome with high morbidity and mortality, distinguished by its unique progression of multi-system derangements^{1,2}. 95 96 Variable degrees of hypothalamic and presumed brainstem dysfunction manifest after 97 age two as obesity, autonomic dysregulation and alveolar hypoventilation with risk of 98 sudden death from respiratory or autonomic dysfunction¹⁻⁶. Neuropsychiatric changes 99 and seizures have been described⁷⁻⁸. Detailed longitudinal follow up describing 100 ROHHAD's natural history is limited⁹. Although incurable, early supportive care 101 including respiratory support for hypoventilation may reduce morbidity^{10,11}. Diagnosis 102 remains difficult given lack of biomarkers and overlap with other pediatric disorders 103 including congenital central hypoventilation syndrome (CCHS), Prader-Willi syndrome and other forms of genetic and non-genetic obesity¹²⁻¹⁵. Although recognized as a 104 105 distinct disorder since 2000, ROHHAD is rare with fewer than 200 reported cases^{1,5}. 106 The etiology is unclear.

107 Thus far, most etiologic investigations into ROHHAD have focused on genetic 108 susceptibility, without consistent results¹⁶⁻¹⁹. The presence of neuroblastic tumor (NT) 109 defines a large subset of patients with ROHHAD (30-100% depending on the series), 110 sometimes referred to as ROHHAD-NET^{5,20}. NTs are similarly associated with CCHS, a 111 genetic condition, and opsoclonus-myoclonus syndrome (OMS), an autoimmune 112 paraneoplastic neurological syndrome (PNS)²¹⁻²³. With respect to ROHHAD, several 113 observations suggest an immune-mediated disease, including the presence of 114 oligoclonal bands in cerebrospinal fluid (CSF) and immune-cell infiltrates in brain,

including hypothalamus and brainstem at autopsy²⁴⁻²⁹. In addition, some patients with 115 116 ROHHAD have variable improvement with immunotherapy^{7,30,31}. Establishing ROHHAD 117 as a PNS would have important implications for developing diagnostic biomarkers. 118 highlighting the need for tumor identification and resection, and advancing the use of 119 immunosuppressive treatments³². 120 121 On a molecular level, a PNS can be defined by its association with autoantibodies to 122 specific onconeural antigens, or proteins expressed in both the pathogenic tumor and healthy nervous system³³. Despite a suspicion of PNS in ROHHAD^{29,34}, evidence of 123 124 anti-neural reactivity is limited and an associated onconeural antigen has not been 125 identified. Here, we deployed human-specific phage-display immunoprecipitation and 126 next-generation sequencing (PhIP-Seg) and complementary techniques to investigate a 127 possible paraneoplastic etiology in ROHHAD. We find that autoantibodies to protein Zinc finger and SCAN domain-containing protein 1 (ZSCAN1) are robustly associated 128 129 with ROHHAD and may be useful as a diagnostic biomarker and advancing knowledge

130 of this poorly understood disease.

131

132 Results

133 Clinical profile of ROHHAD cohort

The ROHHAD cohort consisted of 9 patients (ROHHAD-1 through 9) selected on the
basis of clinical suspicion for ROHHAD syndrome, without alternative diagnosis
(Table1). Each patient was found to exhibit defining features of ROHHAD syndrome
including rapid-onset of obesity between 2-5 years of age and multiple additional

138 features of hypothalamic dysfunction (Table1). Three patients were described 139 previously^{1,7,35}. Hypoventilation was present in 8/9 at diagnosis. Eight of 9 patients were 140 found to have NT (ROHHAD-1 through 8), while a single patient in this cohort was not 141 known to have a tumor (ROHHAD-9), although work-up was limited to chest x-ray and 142 chest MRI without abdominal imaging. Eight of 9 subjects had clinical genetic testing 143 without genetic syndromes identified to explain their phenotypes. Features suggestive 144 of a neuroinflammatory process include comorbid autoimmune diseases (2/9), elevated CSF neopterin (3/9), marked inflammation noted within resected tumor tissue (4/8) and 145 146 matched or CSF-specific oligoclonal bands (5/8 tested). Improvement in symptoms was 147 observed in 6/7 patients treated acutely with supportive care, tumor resection and 148 immune therapy at diagnosis. Response to immunotherapy was most clearly 149 demonstrated in ROHHAD-6 in whom CO₂ retention improved and worsened in parallel 150 with changing steroid doses (Supplemental Figure 1). Similarly, neurobehavioral 151 symptoms improved for ROHHAD-7⁶. Additional clinical details pertaining to 152 autoimmune features and neurologic phenotypes for the ROHHAD cohort are provided 153 in Supplemental Table 1 and Supplemental Table 2, respectively. 154

155 Clinical profile of control cohorts

156 Control cohort 1 (CC1) and control cohort 2 (CC2) were assembled for PhIP-seq

157 screening and validation experiments, respectively. CC1 represents plasma from 100

de-identified blood donors courtesy of New York Blood Center. CC2 represents 27 de-

identified healthy volunteers (plasma n =3; sera n = 17, CSF n =7) and 26 clinically

relevant pediatric controls, Pediatric controls include: childhood obesity + NT (n =1), and

161	children with OMS	with NT n = 10, without NT n=	15). Clinical details and demographics

- 162 pertaining to controls is provided in Supplemental Table 3 (CC1) and Supplemental
- 163 Table 4 (Pediatric controls OMS and Obesity +NT).
- 164

165 Screening for autoantibodies using rodent based approaches

- 166 Immunohistochemical screening of patient antibodies against neural tissue, typically
- 167 rodent, is a classical approach for identifying cryptic autoimmune etiologies among
- ¹⁶⁸ idiopathic neurological syndromes³⁶⁻⁴⁰. In two independent laboratories (JLD, SJP),
- antibodies in CSF from ROHHAD-1 through 6 were tested for immunoreactivity against
- 170 mouse brain tissue (Supplemental Methods). Neither identified anti-neural reactivity in
- any patient (Supplemental Figure 2). Additional, independent assessment of
- 172 autoantibodies to extracellular neural targets were also tested in 4 patients in this cohort
- 173 using pre-established protocols for fixed³⁹ and live rat neurons⁴⁰. All studies were
- 174 negative (JD, see supplemental Table 1).
- 175

176 Screening for autoantibodies using human-specific Phage-Display

177 Immunoprecipitation and Sequencing (PhIP-Seq)

178 The PhIP-seq library employed here displays a representation of the human proteome

and has been used previously for detecting diagnostic PNS autoantibodies ⁴⁰⁻⁴¹. As part

- 180 of a discovery pilot, we screened CSF from 3 ROHHAD patients (ROHHAD 1-3) and
- 181 plasma from CC1 (n=100). Individual PhIP-seq datasets were normalized to 100,000
- reads (RP100K) and protein RP100Ks were averaged according to cohort. To aid in
- 183 candidate identification, ROHHAD-specific Z-score enrichments were generated, using

184 CC1 values (see methods). All proteins with a ROHHAD mean RP100K > 0 were 185 plotted relative to Z-score enrichments (Figure 1). Candidate antigens were expected to 186 satisfy the following criteria in at least 2 patients: a minimum level of recovery 187 (RP100K>50) and minimum Z-score enrichment (>3). Of the ~20,000 protein 188 possibilities, only 1 protein, ZSCAN1, satisfied these criteria. Using the same criteria 189 above, enrichment of ZSCAN1 was not observed in other previously published 190 autoimmune cohorts screened on the same PhIP-Seq platform including PNS syndromes anti-Yo (n= 36)⁴¹, anti-Hu (n= 44)⁴¹, anti-Ma2 (n =2)⁴², anti-KLHL11 (n =7)⁴² 191 192 or patients with systemic Autoimmune Polyglandular Syndrome Type I (n=39)⁴³. 193 194 **Orthogonal validation assays** 195 To further investigate the association of ZSCAN1 and ROHHAD syndrome, we repeated 196 PhIP-seq with an expanded ROHHAD cohort (including the 4 original patients) and new 197 set of controls (CC2). For all samples, ZSCAN1 RP100K is reported, as well as, Z-score 198 enrichment based on our background control dataset CC1 (ZSCAN1 mean = 8.18 199 RP100K, standard deviation = 32.53 RP100K), with Z-score > 3 considered positive. 200 We reproduced the association between ZSCAN1 and ROHHAD, showing enrichment 201 in 7 of 9 ROHHAD patients (ROHHAD-1 to 7) and 0 of 50 samples from CC2 (Figure 2, 202 top). We next leveraged peptide-level data and found antigenicity within ZSCAN1 was 203 largely restricted to the C-terminal of ZSCAN1, with patients displaying enrichment of 204 overlapping peptides, increasing confidence in our findings (Supplemental Figure 3). 205 Intriguingly, patients ROHHAD-1 through 7 shared a common 11 amino acid (AA) 206 epitope.

207

208	To confirm ZSCAN1 enrichment in our ROHHAD cohort was antibody-mediated, we
209	tested for IP of recombinant ZSCAN1 in two orthogonal assays, including a radioligand
210	binding assay (RLBA) and 293T cell-based overexpression assay (CBA). For the 6
211	patients with paired CSF and sera (ROHHAD 1-6), ZSCAN1 enrichment in one sample
212	type was sufficient to be called positive in a given assay. First, the RLBA with in vitro
213	transcribed and translated full length ZSCAN1 protein revealed positive IP (fold change
214	> 10) by ROHHAD patients 1 through 7 (sera n = 7/7; paired CSF n = 6/6) and no
215	enrichment in CC2 healthy controls (Figure 2B). Low-level enrichment of ZSCAN1 was
216	observed in 2 patients negative by PhIP-seq; ROHHAD-9 and OMS-4. Second, using
217	immunocytochemistry and 293T cells expressing full-length ZSCAN1, we show
218	colocalization of human antibodies with commercial antibody to ZSCAN1 for ROHHAD
219	patients 1 through 7 (sera n=2 ROHHAD-1 and 3; CSF n = 6 ROHHAD-1 through 6).
220	Co-localization is not observed for ROHHAD-8, ROHHAD-9 or controls, including OMS-
221	4 (Figure 2C). Taken together, ROHHAD-1 through 7 reproduced ZSCAN1 enrichment
222	in two antibody-based orthogonal assays, thus limiting possibility of false-positives and
223	validating autoantibodies to ZSCAN1 in this cohort ⁴⁴ .
224	

224

Of note for 293T CBAs, we observed increased sensitivity to ZSCAN1 autoantibody
detection using CSF compared to sera. This is exemplified best in data collected from
the 6 patients with paired CSF and sera (ROHHAD-1 through 6). In 293T CBAs,
ZSCAN1 autoantibodies were detected using 6/6 CSF samples (Supplemental Figure
In contrast, only 2/6 paired sera were positive (Supplemental Figure 5). To rule out

230 technical artifacts, sera samples were re-tested on CBA at several dilutions 1:100, 231 1:1000, 1:2000 and 1:5000, with no change in seronegativity. We further tested for 232 recognition of ZSCAN1 autoantibodies using whole cell lysates prepared from 293T 233 cells overexpressing ZSCAN1. When western blotting denatured lysates with CSF and 234 sera we again observed positive signal with 6/6 CSF but only 2/6 paired sera 235 (Supplemental Figure 6). 236 237 Testing antigen expression in tumor and brain 238 Typically, autoantibodies associated with PNS target antigens that are expressed in 239 relevant tumor and healthy brain, otherwise known as onconeural antigens³⁸. To test for 240 tumor expression of ZSCAN1, one NT from ROHHAD-3 was sectioned and 241 immunostained with a previously validated commercial antibody to ZSCAN1 242 (Supplemental Figure 4 through 6). A rabbit secondary only control was used to test for 243 nonspecific staining of Rabbit IgG to infiltrating human IgG and Fc proteins in the tumor. 244 ZSCAN1 expression was apparent in the ROHHAD-associated tumor (Figure 3). To test 245 for hypothalamic expression of ZSCAN1, mass spectrometry analysis was performed 246 using immunoprecipitation from human hypothalamic lysates using commercial 247 antibodies to ZSCAN1. ZSCAN1 peptides were readily detectable, consistent with 248 protein expression in this tissue (Supplemental Table 5). 249 250 Discussion

In this work, we describe a proteome-wide screen for autoantibodies in patients with

252 ROHHAD, a complex, diagnostically challenging syndrome with severe and often life-

threatening symptoms^{1,2}. By comparing antibody profiles from ROHHAD patients to a
large set of clinically relevant controls, we found autoantibodies to ZSCAN1 are a
putative biomarker of ROHHAD, and thus have potential utility in identifying ROHHAD
earlier in the disease course.

257

258 All patients in this ROHHAD cohort (n = 9/9) exhibited the defining symptoms of the 259 syndrome including rapid-onset obesity and hypothalamic dysfunction, with an onset between two to five years of age^{1,2}. NTs were present in 8/9 patients. Autoantibodies to 260 261 ZSCAN1 were identified in 7 of 9 patients tested (sera n=7/9, paired CSF n=5/6) by 262 PhIP-Seq, all of whom had NTs. Each of the 7 PhIP-Seq positive samples (ROHHAD-1 263 through 7) were validated by at least two orthogonal assays, including 293T CBA and 264 RLBA. Two assay validation limits the possibility of false-positive results and is increasingly accepted as a prerequisite for defining bona fide autoantigens^{36,44}. 265 266 267 Two ROHHAD patients (ROHHAD-8 and 9) were negative for ZSCAN1 autoantibodies, 268 although CSF was not available for testing. Interestingly, ROHHAD-8 was in clinical 269 remission when their sera was collected and at an older age compared to other patients 270 (age range = 2 - 10 years, median 3 years), who all exhibited active symptoms at 271 sample collection. ROHHAD-9 did not have a tumor identified but exhibited the 272 ROHHAD phenotype and active disease. Future experiments to determine the 273 association of ZSCAN1 antibodies and ROHHAD syndrome in the absence of NT are 274 warranted.

275

276 Previous clinical reports suggested ROHHAD could be a PNS by virtue of its co-277 occurrence with a tumor type already associated with a different PNS (OMS), clinical 278 features of autoimmunity and the failure to identify consistent genetic associations^{3,7,8,16-} 279 ^{19,24,26-31}. Our findings collectively support the notion of a PNS etiology. First, 280 autoantibodies to the molecular antigen (ZSCAN1) were found in the majority (7/9) of 281 ROHHAD cases, and in all from cases with a NT identified. Second, ZSCAN1 282 expression in human hypothalamus is consistent with the target tissues affected in ROHHAD patients. Third, ZSCAN1 was found to be expressed in NT tissue from a 283 284 patient with ROHHAD. Lastly, the presumed intracellular localization of ZSCAN1 285 (www.uniprot.org, www.proteinatlas.org), together with our expression in ROHHAD NTs 286 as well as healthy nervous system tissue, is reminiscent of other classical PNS 287 onconeural antigens. Antibodies to intracellular onconeural antigens are a biomarker for 288 a major subtype of PNS, such as cerebellar degeneration-related protein 2-like in anti-289 Yo PNS and neuronal ELAV-like proteins 2,3,4 in anti-Hu PNS³³. In these cases, 290 autoantibodies themselves are not thought to be directly pathogenic, and the diseases 291 are often less consistently responsive to tumor resection and immunotherapy compared 292 to PNS with antibodies to extracellular antigens. Consistent with the hypothesis of PNS, 293 ROHHAD patients have variable responses (duration and magnitude) to immunotherapy or tumor resection and may respond better to earlier, more aggressive regimens^{3,7,30,31}. 294 295 296 The ZSCAN1 protein is a putative zinc finger transcription factor (znTF) that contains a 297 single SCAN domain and 3 Cysteine₂-Histidine₂ (C_2H_2) zinc finger domains

298 (uniprot.org). Despite nearly equal representation of SCAN domain (84 AA) and C_2H_2

299	domains (100 AA), antigenicity in ZSCAN1 is biased to the C_2H_2 domains, a functional
300	region for DNA and RNA binding ⁴⁵ . Further, although ~ 700 human proteins containing
301	C_2H_2 domains with the motif C-X ₂₋₄₋ C-X ₁₂₋ H-X ₂₋₆₋ H (where X is any AA) are present in
302	our PhIP-seq library, no other ZnTF's were significantly enriched in more than one
303	patient (Z-score > 1), highlighting the specificity of the motif identified by PhIP-Seq.
304	Importantly, the ZSCAN1 gene lacks a genetic ortholog in rodents, including mice and
305	rats, with evolutionary divergence towards primate-specificity in the C_2H_2 region ⁴⁵⁻⁴⁸ .
306	These observations suggest the putative epitope within ZSCAN1 has a high likelihood
307	of being exclusive to primate. To our knowledge, a primate-specific epitope in
308	autoimmune disease has not yet been described.
309	
310	
510	A common autoantibody among ROHHAD patients suggests a route to a molecular
311	A common autoantibody among ROHHAD patients suggests a route to a molecular diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach
311	diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach
311 312	diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach for ROHHAD biomarker discovery. <i>ZSCAN1</i> has no genetic ortholog in rodents, so the
311312313	diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach for ROHHAD biomarker discovery. <i>ZSCAN1</i> has no genetic ortholog in rodents, so the classical rodent based approach for PNS autoantibody detection failed. Our results
311312313314	diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach for ROHHAD biomarker discovery. <i>ZSCAN1</i> has no genetic ortholog in rodents, so the classical rodent based approach for PNS autoantibody detection failed. Our results suggest CBAs or RLBAs on CSF may be sufficient to detect ZSCAN1 autoantibodies in
 311 312 313 314 315 	diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach for ROHHAD biomarker discovery. <i>ZSCAN1</i> has no genetic ortholog in rodents, so the classical rodent based approach for PNS autoantibody detection failed. Our results suggest CBAs or RLBAs on CSF may be sufficient to detect ZSCAN1 autoantibodies in a clinical lab setting. In the case of ROHHAD, these results also suggest that CSF may
 311 312 313 314 315 316 	diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach for ROHHAD biomarker discovery. <i>ZSCAN1</i> has no genetic ortholog in rodents, so the classical rodent based approach for PNS autoantibody detection failed. Our results suggest CBAs or RLBAs on CSF may be sufficient to detect ZSCAN1 autoantibodies in a clinical lab setting. In the case of ROHHAD, these results also suggest that CSF may be the most sensitive sample type for testing, since ZSCAN1 was not always detectable

To summarize, we provide a robust finding of autoantibodies to ZSCAN1 as a marker
for tumor-associated pediatric ROHHAD. ZSCAN1 expression in tumor and human
hypothalamus provides further evidence to support the clinical suspicion that ROHHAD

322	is a novel type of PNS. This is the first identified intracellular antigen in a PNS unique to
323	children. Further experiments are required to test the utility of ZSCAN1 autoantibodies
324	for diagnosis in ROHHAD patients with and without tumors, define the clinical spectrum
325	of PNS ROHHAD and to understand how immune targeting of ZSCAN1 contributes to
326	the dramatic clinical complications seen in patients with ROHHAD syndrome.
327	
328	Methods
329	All relevant ethical regulations were followed regarding animal experiments and human
330	research participant involvement. We have obtain informed consent from all
331	participants and/or their parents.
332	
333	Patient recruitment
334	All local IRB regulations were followed at Boston Children's Hospital (protocol #09-02-
335	0043) and University of California, San Francisco (protocol #13-12236). All patient
336	specific data was extracted by chart review (LB, LK, ST) and samples obtained
337	following family consent. ROHHAD subjects were identified by pediatric neuro-
338	immunologists (L.B. or S.T.) on the basis of clinical suspicion for ROHHAD syndrome,
339	without alternative diagnosis.
340	
341	Autoantibody discovery and validation
342	For autoantibody discovery, we utilized the PhIP-Seq library and experimental protocol
343	as previously described. ⁴² PhIP-seq datasets were analyzed with a formalized analysis
344	pipeline (generated in-house) that includes alignment of DNA reads to input library ⁴⁹ ,

345 conversion to peptide reads, summing of peptides by protein ID, normalization to

- 346 100,000 reads (RP100K) and calculating mean RP100K for each protein. Alignment of
- 347 sequencing reads to the input library on a peptide-level was performed with
- 348 RAPsearch2⁴⁹ and command line '/data/bin/rapsearch -d input_library -q
- 349 read1_location -o output_location -z 12 -v 1 -b 0'. A Z-score enrichment for each protein
- 350 was calculated based on mean RP100K generated from a large set of healthy controls.
- 351 Z-score formula = (protein_x mean RP100K_{Experimental} protein_x mean RP100K_{control})/
- 352 (Standard Deviation of protein_X in controls).
- 353

354 Onconeural antigen investigation

355 To examine candidate autoantigen expression in ROHHAD tumor and healthy human

356 brain we used immunohistochemistry and immunoprecipitation-mass spectrometry (IP-

357 MS), respectively. For tumor examination, fresh frozen tumor was embedded,

358 sectioned, fixed on slides, stained and imaged according to standard procedures

359 (Supplemental Methods). To detect ZSCAN1 we immunostained with commercial

antibody to ZSCAN1 (Rabbit, Thermo Fisher Scientific, PA552488) and anti-rabbit

361 secondary. For IP-MS experiments, ~100 milligrams of frozen human hypothalamus

362 was homogenized and prepared for IP and subsequent MS analysis (Supplemental

363 Methods). For IP, lysate was diluted to 0.5 mg/mL and one of the following antibodies

364 was added at 1ug/mL: Rabbit anti-ZSCAN1 (Thermo Fisher Scientific, PA552488),

- 365 Rabbit anti-ZSCAN1 (Sigma Aldrich HPA007938), Rabbit IgG control (Thermo Fisher
- 366 Scientific, 31235). Positive identification of ZSCAN1 required detection with two

- 367 commercial antibodies and absence from isotype control. Two technical replicates were368 performed.
- 369

370 Animal Protocol

- 371 All animal protocols were in accordance with the regulations of the National Institute of
- Health and approved by the University of California San Francisco Institutional Animal
- 373 Care and Use Committee (IACUC). Wildtype C57B6 mice were obtained from Jackson
- 374 Laboratories (Bar Harbor, ME, USA). Adult mice (> postnatal day 42) were used for
- 375 immunohistological screening of human patient antibodies.
- 376

377 Data availability

- 378 Original data contributing to the main findings in our study is provided on Dryad
- 379 repository (temporary link for review: <u>https://datadryad.org/stash/share/-</u>
- 380 vpGCICcsEFX1bVTwmPAqh3K_6errf8vkOo6k3vPnUk). The dryad repository includes
- 381 PhIP-Seq analysis and RLBA analysis of ZSCAN1 (Figure 1, Figure 2 a,b), Mass
- 382 Spectrometry search results (Supplemental Table 5), original microscopy images
- 383 (Figure 2c, Supplemental Figure 2,4,5), original blots (Supplemental Figure 6). There
- 384 are no data restrictions for this study.
- 385

386 Additional Methods

- 387 Full experimental details regarding PhIP-Seq screening for candidate autoantibodies,
- 388 orthogonal validation assays, indirect immunofluorescence screening for anti-neural

- 389 antibodies on rodent tissue, immunohistochemistry of ROHHAD tumor tissue and IP-MS
- 390 of human brain are provided in Supplemental Methods.
- 391

392 **References**

- 393 1. Katz, E.S., Mcgrath, S., Marcus, C.L. Case Reports Late-Onset Central
- 394 Hypoventilation With Hypothalamic Dysfunction: A Distinct Clinical Syndrome.
- 395 *Pediatr Pulmonol.* 68, 62-8 (2000).
- 396 2. Ize-Ludlow, D., et al. Rapid-onset obesity with hypothalamic dysfunction,
- 397 hypoventilation, and autonomic dysregulation presenting in childhood. *Pediatrics*
- 398 120, e179-88 (2007).
- 399 3. Ibáñez-Micó, S., et al. Rapid-onset obesity with hypothalamic dysregulation,
- 400 hypoventilation, and autonomic dysregulation (ROHHAD syndrome): A case

401 report and literature review. *Neurologia.* 32,616-622 (2017).

- 402 4 Patwari, P.P. & Wolfe, L. Rapid-onset obesity with hypothalamic dysfunction,
- 403 hypoventilation, and autonomic dysregulation: review and update. *Curr Opin*

404 *Pediatr.* 26, 487-92 (2014).

- 405 5. Lee, J.M., et al. Rapid-Onset Obesity with Hypoventilation, Hypothalamic,
- 406 Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET)
- 407 Syndrome: A Systematic Review. *Biomed Res Int* 2018, 1-17 (2018).
- 408 6. Chew, H.B., Ngu, L.H., Keng, W.T. Rapid-onset obesity with hypothalamic
- 409 dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): a case
- 410 with additional features and review of the literature. *BMJ Case Rep.* 2011 (2011).

411	7.	Jacobson, L.A.	, et. al. Im	proved Behavior	and Neuropsy	/chological	Function in

- 412 Children With ROHHAD After High-Dose Cyclophosphamide. *Pediatrics* 138,
- 413 e20151080-e20151080 (2016).
- 414 8. Sethi, K., et al. ROHHADNET Syndrome Presenting as Major Behavioral
- 415 Changes in a 5-Year-Old Obese Girl. *Pediatrics* 134, e586-9 (2014).
- 416 9. Eldin, A.W.J., et al. Natural history of ROHHAD syndrome: development of
- 417 severe insulin resistance and fatty liver disease over time. *Clin. Diabetes*
- 418 *Endocrinol.* 5, 9 (2019).
- 419 10. Stowe, R.C. & Afolabi-Brown, O. Pulmonary hypertension and chronic
- 420 hypoventilation in ROHHAD syndrome treated with average-volume assured
- 421 pressure support. *Pediatr. Investig.* 3, 253-256 (2019).
- 422 11. Selvadurai, S., et al. Sleep-disordered breathing, respiratory patterns during
- 423 wakefulness and functional capacity in pediatric patients with rapid-onset obesity
- 424 with hypothalamic dysfunction, hypoventilation and autonomic dysregulation
- 425 syndrome. *Pediatr. Pulmonol.* 56, 479-485 (2021).
- 426 12. Kocaay P., Şıklar Z., Çamtosun E., Kendirli T., Berberoğlu, M. ROHHAD
- 427 Syndrome: Reasons for Diagnostic Difficulties in Obesity. *J Clin Res Pediatr*
- 428 *Endocrinol.* 6, 254-257 (2016).
- 429 13. Barclay, S.F., et al. ROHHAD and Prader-Willi syndrome (PWS): Clinical and
 430 genetic comparison. *Orphanet J Rare Dis* 13, 1-9 (2018).
- 431 14. Barclay, S.F., et al. Absence of mutations in HCRT, HCRTR1 and HCRTR2 in
- 432 patients with ROHHAD. *Respir Physiol Neurobiol* 221, 59-63 (2016).

433	15	Cielo, C. and Marcus, C.L. Central Hypoventilation Syndromes. Sleep Med Clin.
434		9, 105-118 (2014).

- 435 16. Barclay, S.F., et al. Rapid-Onset Obesity with Hypothalamic Dysfunction,
- 436 Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of
- 437 trios, monozygotic twins and tumours. Orphanet J Rare Dis 10, 103 (2015).
- 438 17. Patwari, P.P., Rand, C.M., Berry-Kravis, E.M., Ize-Ludlow, D., Weese-Mayer,
- 439 D.E. Monozygotic twins discordant for ROHHAD phenotype. *Pediatrics* 128,
- 440 e711-5 (2011).
- 441 18. Rand, C., et al. Rapid-Onset Obesity With Hypothalamic Dysfunction,

442 Hypoventilation, and Autonomic Dysregulation: Analysis of Hypothalamic and

443 Autonomic Candidate Genes. *Pediatr Res* 70, 375-378 (2011).

- 444 19. Thaker, V.V., et al. Whole exome sequencing identifies RAI1 mutation in a
- 445 morbidly obese child diagnosed with ROHHAD syndrome. *J Clin Endocrinol* 100,
 446 1723-30 (2005).
- 447 20. Harvengt, J., et al. ROHHAD(NET) Syndrome: Systematic Review of the Clinical
- 448 Timeline and Recommendations for Diagnosis and Prognosis. J. Clin.
- 449 *Endocrinol. Metab.* 105, 2119-2131 (2020).
- 450 21. Zaidi, S., Gandhi, J., Vatsia, S., Smith, N.L., Khan, S.A. Congenital central
- 451 hypoventilation syndrome: An overview of etiopathogenesis, associated
- 452 pathologies, clinical presentation, and management. Auton Neurosci. 210,1-9
- 453 (2018).

454	22.	Meena, J.P., et. al. Neuroblastoma presenting as opsoclonus-myoclonus: A
455		series of six cases and review of literature. J Pediatr Neurosci. 11, 373-377
456		(2016).
457	23.	Rudnick, E., et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma:
458		Clinical outcome and antineuronal antibodies-a report from the children's cancer
459		group study. Med Pediatr Oncol. 36, 612-22 (2001).
460	24.	Gharial, J. et al. Neuroimaging and Pathology Findings Associated With Rapid
461		Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic
462		Dysregulation (ROHHAD) Syndrome. J. Pediatr. Hematol. Oncol. 43, e571-e576
463		(2020).
464	25.	Nunn, K., Ouvrier, R., Sprague, T., Arbuckle, S., Docker, M. Idiopathic
465		Hypothalamic Dysfunction: A Paraneoplastic Syndrome? Journal of Child
466		Neurology 12, 276-281 (1997).
467	26.	Cemeroglu, A.P., Eng, D.S., Most, L.A., Stalsonburg, C.M., Kleis, L. Rapid-onset
468		obesity with hypothalamic dysfunction, hypoventilation, and autonomic
469		dysregulation syndrome and celiac disease in a 13-year-old girl: Further
470		evidence for autoimmunity? J Pediatr Endocrinol Metab 29, 97-101 (2016).
471	27.	Sirvent, N., et al. Hypothalamic dysfunction associated with neuroblastoma:
472		evidence for a new Paraneoplastic syndrome? Med Pediatr Oncol 40, 326-8
473		(2003).
474	28.	Sartori, S., et al. Intrathecal synthesis of oligoclonal bands in rapid-onset obesity
475		with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation

- 476 syndrome: new evidence supporting immunological pathogenesis. *J Child Neurol*477 29, 421-5 (2014).
- 478 29. Armangue, T., Petit-Pedrol, M., Dalmau J. Autoimmune encephalitis in children. J
- 479 *Child Neurol.* 27, 1460-9 (2012).
- 480 30. Paz-Prie, I.I, Cooke, D.W., Chen, A.R. Cyclophosphamide for rapid-onset
- 481 obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation
 482 syndrome. *J Pediatr* 158, 337-9 (2011).
- 483 31. Huppke, P., Heise, A., Rostasy, K., Huppke, B., Gärtner, J. Immunoglobulin
- 484 therapy in idiopathic hypothalamic dysfunction. *Pediatr Neurol* 41, 232-4 (2009).
- 485 32. Voltz, R. Paraneoplastic neurological syndromes: an update on diagnosis,
- 486 pathogenesis, and therapy. *Lancet Neurol.* 1, 294-305 (2002).
- 487 33. Dalmau, J., and Graus, F. Antibody-Mediated Encephalitis. *New Engl J Med* 378,
 488 840-851 (2018).
- 489 34. Giacomozzi, C., et al. Anti-Hypothalamus and Anti-Pituitary Auto-antibodies in
- 490 ROHHAD Syndrome: Additional Evidence Supporting an Autoimmune
- 491 Etiopathogenesis. Horm.Res. Paediatr. 92, 124-132 (2019).
- 492 35. Rathore, G.S., Thompson-Stone, R.I., Benson, L. Chapter 20: Rapid-Onset
- 493 Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic
- 494 Dysregulation (ROHHAD). In Waubant E, Lotze TE, eds: Pediatric Demyelinating
- 495 Diseases of the Central Nervous System and Their mimics: A Case-Based
- 496 Clinical Guide Edition 1. *Springer International Publishing* 159-16 (2017).

- 497 36. Dalmau, J. and Posner, J.B. Neurologic paraneoplastic antibodies (anti-Yo; anti-
- 498 Hu; anti-Ri). The case for a nomenclature based on antibody and antigen
- 499 specificity. *Neurology* 44, 2241 (1994).
- 500 37. Vanda A. Lennon. The case for a descriptive generic nomenclature
- 501 Clarification of immunostaining criteria for PCA-1, ANNA,-1, and ANNA-2
- 502 autoantibodies. *Neurology* 44, 2412 (1994).
- 38. Darnell, R.B. & Posner, J.B. Paraneoplastic Syndromes Involving the Nervous
 System. *N Engl J Med.* 16; 349, 1543-1554 (2003).
- 505 39. Ances, B.M., et. al. Treatment-responsive limbic encephalitis identified by
- 506 neuropil antibodies: MRI and PET correlates. *Brain* 128, 1764-1777 (2005).
- 40. Lai, M., et. al. AMPA receptor antibodies in limbic encephalitis alter synaptic
 receptor location. *Ann Neurol* 65, 424-434 (2009).
- 509 41. O'Donovan, B., et al. High-resolution epitope mapping of anti-Hu and anti-Yo
- 510 autoimmunity by programmable phage display, *Brain Communications*, 3;2,
- 511 fcaa059 (2020).
- 512 42. Mandel-Brehm, C., et al. Kelch-like Protein 11 Antibodies in Seminoma-
- 513 Associated Paraneoplastic Encephalitis. *N Engl J Med.* 4;381(1), 47-54 (2019).
- 43. Vazquez, S.E., et al. Identification of novel, clinically correlated autoantigens in
 the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife*
- 516 9, e55053 (2020).
- 517 44. Ruiz-García, R., Martínez-Hernández, E., Saiz, A., Dalmau, J., Graus, F. The

518 Diagnostic Value of Onconeural Antibodies Depends on How They Are Tested.

519 *Front Immunol.* 11, 1482. (2020).

520	45.	Luchi. S. Three classes of C2H2 zinc finger proteins. CMLS, Cell Mol. Life Sci.
521		58, 625-635 (2001).
522	46.	Dehal, P., et.al. Human chromosome 19 and related regions in mouse:
523		conservative and lineage-specific evolution. Science 293(5527):104-11. (2001)
524	47.	Edelstein, L.C. & Collins, T. The SCAN domain family of zinc finger transcription
525		factors. Gene 10, 359:1-17 (2005).
526	48.	Sander, T.L., et al. The SCAN domain defines a large family of zinc finger
527		transcription factors. Gene 310, 29-38 (2003).
528	49.	Zhao, Y., et. al. RAPSearch2: a fast and memory-efficient protein similarity
529		search tool for next-generation sequencing data. Bioinformatics. 28,125-6
530		(2012).
531		

532 Acknowledgements

533 This research was supported by ROHHAD Fight, Inc. the OMS Life Foundation, the 534 Repository Core for Neurological Disorders, Department of Neurology, Boston 535 Children's Hospital, and the IDDRC (NIH P30HD018655) and NIH R01MH122471. We 536 would also like to acknowledge the New York Blood Center for contribution of healthy 537 control plasma. Instituto Carlos III (ISCIII, PI20/00197 [JD]), and "La Caixa" Foundation 538 (JD). CMA is supported by NIDDK (K23DK120899). Acknowledge the UCSF Nikon 539 Core Facility for microscope imaging equipment and guidance. JDL is funded by a grant 540 from Chan Zuckerberg Biohub. JDL, MRW, SJP and CMB are funded by the National 541 Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471-01). SJP, BT are 542 also funded by the Brain Research Foundation (Scientific Innovations Award). CMB is

543	also funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and
544	by the National Institute of Neurological Disorders and Stroke (NINDS) of the National
545	Institutes of Health (award 1K99NS117800-01). SEV is funded by the National Institute
546	of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915-01).
547	
548	Author contributions:
549	CMB, LB and BT contributed equally to this work.

1 Main Figure and Tables

				ROHHAD Symptom	S			Τ
Patient No. and sex	Sample Type	Rapid- Onset Obesity?	Respiratory phenotype	Endocrinopathies†	Autonomic Dysfunction	Tumor Type and CSF Results	Treatments#	Outcome
1 (F)	CSF, Serum	Yes	CSA, 24 hour hypoventilation	Thirst dysregulation, AVP dysregulation (with DI and SIAD), hyperprolactinemia, HH, GHD, CH, CAI, obesity (Z=+2.5, peak +2.7), IR, T2D (metformin, insulin, GLP1RA)	Temperature and heart rate dysregulation, enuresis, duodenal pseudoobstruction	Ganglioneuroma; 1 white blood cell/m ³ , 8 red blood cells/m ³ , 0 OCBs	Tumor resection, trach/vent, IVIG, rituximab, MMF	Alive
2 (F) ³⁵	CSF, Serum	Yes	Night-time hypoventilation	Hyperprolactinemia, HH, GHD, obesity (Z=+2.4, peak +3.1), IR, prediabetes	Constipation, encopresis	Ganglioneuroma; 0 white blood cell/m ³ , 54 red blood cells/m ³ , matched CSF and serum OCBs	Tumor resection, CPAP, IVIG, Rituximab	Alive
3 (M)	CSF, Serum	Yes	CSA, 24 hour hypoventilation	Thirst dysregulation, AVP dysregulation (with DI and SIAD), prepubertal gonadotropins, GHD, CH, CAI (partial), obesity (Z=+2.6, peak +5.2)	Temperature instability, heart rate variability, severe constipation with rectal prolapse, episodic diaphoresis	Neuroblastoma; 5 white blood cell/m3, 525 red blood cells/m3, 13 OCBs at diagnosis	Tumor resection, trach/vent, IVIG, rituximab	Sudden death
4 (M)	CSF, Serum, Tumor	Yes	CSA, 24 hour hypoventilation	Hyperprolactinemia (resolved), obesity(Z=+3.1, peak +3.7)	Hypertension, severe paroxysmal sympathetic hyperactivity at times with flash pulmonary edema, (GI dysmotility	Ganglioneuroblas toma; 4 white blood cell/m3, 2 red blood cells/m3, 2 OCBs (normal), neopterin 20 (normal)	Tumor resection, trach/vent, methylprednis olone, IVIG, rituximab	Alive

					post arrest, improved)			
5 (M)	CSF, Serum, Tumor	Yes	CSA, 24 hour hypoventilation	SIAD, hyperprolactinemia, CH, obesity (Z=+4.7, peak 6.1)	Blood pressure, heart rate and temperature instability (severe hyperthermia up to 108F w/ brain injury), episodic diaphoresis	Ganglioneuroblas toma; 0 white blood cell/m3, 0 red blood cells/m3, 0 OCBs, neopterin 41 (normal) (repeat LP after 5.5 months similar now with matched CSF and serum OCBs)	Tumor resection, trach/vent, dexamethason e, IVIG, rituximab, high dose cyclophospha mide	Alive, severe debilitatio n and behavior problems
6 (M)**	CSF, Serum	Yes	24 hour hypoventilation	Thirst dysregulation, AVP dysregulation (with DI), hyperprolactinemia, CH, obesity (Z=+1.7, peak +3.9)	Transient temperature instability at diagnosis, episodic diaphoresis (all resolved with treatment)	Ganglioneuroblas toma , intermixed; 36 white blood cell/m3, 0 red blood cells/m3, 0 OCBs, neopterin 94 (elevated)	Tumor resection, BiPAP, dexamethason e, IVIG, rituximab	Alive
7 (F) ⁷	Serum	Yes	OSA	DI (partial)	None	Ganglioneuroblas toma	Rituximab, high dose cyclophospha mide	Alive
8 (F) ¹	CSF, Serum	Yes	24 hour hypoventilation	Mild hyperprolactinemia, Hypothyroidism, central precocious puberty, later amenorrhea, GHD, obesity (BMI 38.7 kg/m2 adulthood), recurrent hypoglycemia/hypokalemia in adulthood of unclear etiology	None diagnosed/evaluat ed in childhood	Ganglioneuroma ; 2 white blood cell/m3, 60 red blood cells/m3, protein 141, 0 OCBs, neopterin 21 (normal)	Steroids, IVIG, rituximab, thymectomy	Alive

9 (M)	Serum	Yes	CSA, 24 hour hypoventilation	Hypodipsia, AVP dysregulation (with DI and hyponatremia), obesity (Z=+2.7, peak +4.7), IR, T2D (metformin, insulin)	Temperature instability, bradycardia, hypothermia, episodic diaphoresis	None (abdomen not imaged); 2 white blood cell/m3, 31 red blood cells/m3, 1 matched serum to CSF OCB, neopterin 76	IVIG	Sudden death
						(elevated)		

2 Table 1. Clinical profile of ROHHAD cohort.

3 AVP = Arginine Vasopressin, BiPAP= Bilevel Positive Airway Pressure, BMI = Body Mass Index, CAI=central adrenal insufficiency,

4 CH=central hypothyroidism, CSF = Cerebrospinal Fluid, CPAP= Continuous Positive Airway Pressure, CSA= central sleep apnea,

5 DI= diabetes insipidus, GHD=growth hormone deficiency, GLP1RA = Glucagon-like peptide-1 receptor antagonists, LP= Lumbar

6 Puncture, HH=hypogonadotropic hypogonadism, IR=insulin resistance, IVIG = Intravenous Immunoglobulin, OCB = Oligoclonal

7 Band, MMF = Mycophenolate Mofetil, OSA = Obstructive Sleep Apnea, SIAD=syndrome of inappropriate antidiuresis, T2D=type 2

8 diabetes mellitus, trach=tracheostomy, vent = ventilator

9 * All tested CSF had normal protein, glucose and IgG index values except where noted

10 **See Supplemental Figure 1

11 #Endocrine and other symptomatic treatment not recorded.

12 †Body mass index (BMI) z-scores (number of standard deviations from average) based on the 2000 Centers for Disease Control

13 Growth Charts (https://www.cdc.gov/growthcharts/cdc_charts.htm) were abstracted by patient chart review.

14 ^{1,7,35} denote references for patients published previously.



Figure 1: PhIP-Seq screen implicates ZSCAN1 as a candidate autoantigen in ROHHAD. CSF from 3 ROHHAD patients (ROHHAD-1 to 3) and plasma from a large set of "healthy controls" (n = 100) were tested by PhIP-Seq. Individual data was averaged according to cohort. All proteins with a ROHHAD mean RP100K >0 are plotted against ROHHAD Z-score enrichments compared to healthy. Non-ZSCAN1 proteins are denoted with blue dots, ZSCAN1 is denoted with a red dot.



Figure 2. Validation of autoantibodies to ZSCAN1 in ROHHAD patients. In panel a

and b, enrichment of ZSCAN1 by PhIP-Seq and Radio Ligand Binding Assay (RLBA)

was compared between ROHHAD patients (n=9), non-inflammatory healthy controls (n=24) and pediatric controls including children with OMS with and without NT (n=25) and an obesity patient with NT (n=1). Data represents the average of two independent technical replicates. a, PhIP-Seq analysis. Each column represents an individual sample. A heatmap of total ZSCAN1 RP100K is shown in the top row. To enable comparisons between the majority of samples with lower signal we added a ceiling value of 1000 RP100K. Z-score enrichments based on our 100 human donor dataset are plotted below, with samples that have Z-score enrichments > 3 colored with blue squares. Grey squares indicate Z-score < 3. b, RLBA testing immunoprecipitation of recombinant ZSCAN1 by ROHHAD patients and controls. For all samples, fold change was calculated by dividing by the mean value from control sera (n=17, mean = 20.83). c, Representative image showing immunostaining of 293T cells expressing full-length ZSCAN1 with human CSF and commercial antibody to ZSCAN1 (Rabbit). Top row shows immunostaining with control CSF. Bottom row shows staining with ROHHAD-3 CSF. Colocalization is indicated by yellow in the merge images (far right both rows).



Figure 3. Immunohistochemical detection of ZSCAN1 in NT associated with

ROHHAD patient-3. Fixed NT tissue was immunostained with either (top) Anti-Rabbit-488 secondary alone or (bottom) primary antibody to ZSCAN1 (Rabbit) and Anti-Rabbit-488 Secondary. Green: Anti-Rabbit-488 secondary, Blue: DAPI to identify nuclei.